VeriStrat test saved an average of $1,050 per patient while improving survival outcomes (as compared to patients treated without the use of the test).
Biodesix will present data from three studies at AACR 2017 annual meeting, on genomic and proteomic assays.
A new study published in Current Medical Research and Opinion shows that VeriStrat changes treatment decisions for patients with lung cancer.
Dr. Jeffrey Weber will present study results of new Biodesix immunotherapy test at ITOC4
Biodesix and Progenetics have entered into an international agreement; Biodesix tests will be available in Israel for the first time.
Biodesix released data at ASCO-SITC on a new assay that measures PD-L1 in the blood of cancer patients.
Biodesix will present data on blood-based diagnostic testing for PD-L1 at ASCO-SITC 2017; ddPCR test measuring mRNA expression from immune and cancer cells
Biodesix's GeneStrat liquid biopsy test now includes ROS1 and RET mutations. The test helps physicians make treatment decisions for cancer patients.
Clin-TOF successfully integrated into VeriStrat® workflow
Biodesix and Bioyong announced a $38M deal for development and commercialization of VeriStrat in China.